<DOC>
	<DOCNO>NCT01783925</DOCNO>
	<brief_summary>The objective PMS gain information safety efficacy real practice regulatory commitment require MFDS</brief_summary>
	<brief_title>Eylea Post Marketing Surveillance ( PMS )</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<criteria>Patients determine start EYLEA treatment Patients agree sign inform consent Patients receive EYLEA treatment first time Patients meet one follow Patients diagnosed physician neovascular ( wet ) agerelated macular degeneration wAMD Patients diagnose physician visual impairment due macular edema secondary retinal vein occlusion ( branch RVO central RVO ) Patients diagnose visual impairment due diabetic macular edema ( DME ) Patients diagnose visual impairment due myopic choroidal neovascularization ( mCNV ) Patients receive antiVEGF therapy within 90 day Patients contraindicate base approved product label Ocular periocular infection Active severe intraocular inflammation Known hypersensitivity ingredient drug</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>